Genprex reports positive preclinical GPX-002 data in T2D; first NHP achieved normal glucose tolerance at 7 months

Genprex, Inc.

First T2D NHP received intraductal AAV infusion of GPX-002 (Pdx1+MafA) and showed normal glucose tolerance test at 7 months.
Second NHP via direct pancreas injection improved glucose tolerance at 3 months but did not reach normal levels.
T2D mice treated with GPX-002 showed reversal of hyperglycemia and normal glucose levels at 4 weeks post-surgery.
GPX-002 aims to rejuvenate exhausted beta cells; company says data supports potential to address 90-95% of diabetes patients (T2D).
Preclinical studies continuing; formal toxicology and IND submission planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.